Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in BrusselsSAO PAULO - What does sugarcane have to do with Global Warming? Everything, when you consider Brazil’s highly successful, 30-year experience with sugarcane as a feedstock for ethanol. In place since the mid-70s, the largest program in the world to replace a fossil fuel with renewable energy has saved some 600 million tons of greenhouse gas (GHG) emissions. It would take 20 years for six billion trees to achieve the same results. Helsinn Announces New Plans for its Manufacturing OperationsLUGANO, Switzerland - Today the Swiss pharmaceutical group Helsinn announced new plans aimed at creating a competitive Manufacturing Organization focused on highly potent compounds, with strong R&D and production capabilities. Both financial investments and a new organization of the manufacturing sites in Ireland and Switzerland are part of this strategy. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)SAN MATEO, California and STAINES, England - Conference Call Today at 9:00am ET - Covers Europe, Middle East and Africa New Data From CLARITY Study Presented at 19th ENS Meeting Show Rapid and Sustained MS Relapse Reduction for Cladribine TabletsMILAN, Italy and GENEVA, Switzerland - The Effect of Short-course Oral Treatment With Cladribine Tablets on Annualized Relapse Rate was Significant as Early as 12 Weeks After Initiation of Treatment and Sustained Through to the 96 Weeks of the Study CEM Wins Presidential Green Chemistry Challenge Award for the Sprint Rapid Protein AnalyzerMATTHEWS, North Carolina - CEM Corporation has won a 2009 Presidential Green Chemistry Challenge Award in the Greener Reaction Conditions category for its Sprint(TM) Rapid Protein Analyzer. The company will accept the award this evening during a ceremony at the Carnegie Institute for Science (CIS) in Washington, DC. BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic TestsBERLIN, NIMES, France and RICHMOND, California - Diagnostics company BRAHMS Aktiengesellschaft, Cezanne and Lumiphore Inc., a biotechnology leader from California, announced that they have signed an agreement on incorporation of Lumiphore’s Lumi4(R)-Tb complexes in BRAHMS diagnostic tests. Glybera(TM) Shows Long-Term Health BenefitsAMSTERDAM, The Netherlands - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today new data showing that a one-time administration of its lead product GlyberaTM results in significant long-term health benefits. Long-term follow-up data from two clinical trials show that one administration with GlyberaTM brings significant and clinically important reduction in acute pancreatitis in lipoprotein lipase deficient patients. Recurrent acute pancreatitis is the most debilitating complication of lipoprotein lipase deficiency (LPLD) and is associated with significant morbidity and mortality. These data were presented at the International Symposium on Atherosclerosis in Boston, one on the most prestigious conferences on arterial disease well-attended by expert physicians. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)SEATTLE, Washington, and LEIDEN, The Netherlands - ProFibrix B.V. today announced the start of the company’s Phase II clinical trial for Fibrocaps(TM), the company’s lead topical Hemostat product, with the successful treatment of the first patients for mild to moderate bleeding during liver surgery. ProFibrix expects to complete the study before the end of 2009. New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical DevelopmentDUBLIN - Study Examines Impact of Regulatory Changes on Pharma Industry According to a report issued today, drug safety leaders in pharmaceutical and biotechnology companies recognise the need to increase resources, either internally or through partnerships, to comply with the safety regulations recently issued by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMEA). The report - Safety First: The Impact of New Regulations on Clinical Development - is based on a survey of 140 industry safety specialists, including heads of medical, drug safety, pharmacovigilance, and regulatory departments within large and mid-sized pharmaceutical companies and biotech firms. The survey found that more than three-quarters (77%) of respondents believe that new safety regulations have had a considerable impact on the industry as companies implement drug safety regulations throughout the clinical development process. A Worldwide Milestone in Cell Analysis - 40 Years of Flow CytometryGÖRLITZ, Germany - Biotechnology Company Partec Celebrates Festive Ceremony 2009 is the year of the 40th anniversary since the introduction of the worldwide first fluorescence based flow cytometer - the ICP 11. ISVH Expands Global Reach With New Website, New Offices and Increased International MeetingsST. CLOUD, France - The International Society of Vascular Health (ISVH) announces the launch of a new state-of-the-art website, new offices in France and upcoming international meetings. ISVH increases its global reach with virtual services as well as full-service offices supporting members internationally. SEP Signs REGURIN(R) DealLONDON - Speciality Urology Company Gains Exclusive UK Distribution Rights Speciality European Pharma Limited (SEP), the UK based, urology focused, specialty pharmaceutical company, is pleased to announce that it will obtain the exclusive distribution rights to Regurin(R) (trospium chloride) for the UK and Ireland, as of the 1st July 2009. Regurin, owned by Rottapharm-Madaus, is currently marketed under different brand names in European countries including Germany, Italy, Austria, Spain and Switzerland. New IVF Software MedITEX to be Presented at the ESHRE ExhibitionREGENSBURG, Germany - MedITEX IVF Facilitates Organisation, Documentation and Quality Assurance in the Field of Reproductive Medicine Original or Copy?SEVELEN, Switzerland - Textil-DNA From Schoeller Can Reveal Within Seconds The damage resulting from counterfeit products worldwide is estimated at euro 200 to 300 billion*. It is no longer just a question of copying good designs. Fakes and copies of technical products call the safety of these products into question and, consequently, product liability claims are increasing. At Techtextil in Frankfurt, the Swiss technology company, Schoeller, presented the Textil-DNA project for the first time. Clinical and Histopathological Results Using Pollogen’s TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser TherapyTEL AVIV, Israel - In-vivo Clinical Study Confirms the Efficacy of TriPollar(TM) Technology for Reducing Fat and neo Collagen Generation Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage LeukaemiaOSLO, Norway - New Investigational Drug Also Shown to Improve Remission Rates and Reduce Short-Term Mortality Compared to Previous Treatments BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair DeviceLAVAL, Canada - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced statistically significant results from an analysis of patients who completed their 12 month follow-up in the BST-CarGel(R) randomized clinical trial. Specifically, statistically significant evidence of improved repair tissue quality due to BST-CarGel treatment was found during analyses of tissues biopsied from the knees of 22 patients. The ongoing multicentre pivotal trial is evaluating the ability of BST-CarGel to repair cartilage lesions in the knee when applied to a microfractured lesion compared to microfracture alone (control) in 80 patients. Final results on all 80 patients are expected in the first half of 2010. ICON Announces Collaboration to Develop New Translational Medicine Unit at Purpose-built Hospital Facility in ManchesterDUBLIN - New Facility Part of Ambitious Expansion Plans at Central Manchester University Hospitals Foundation Trust Campus Study Demonstrates Efficacy of Pitavastatin in Elderly PatientsBOSTON - Pitavastatin Represents Important Treatment Option for More Vulnerable Populations New data presented today showed that pitavastatin is an effective treatment for the management of dyslipidaemia in elderly patients, with a similar safety and tolerability profile to low-dose pravastatin. The Phase III data were presented today by Kowa, at the XV International Symposium on Atherosclerosis in Boston. Finesse Solutions Expands Into State-of-the-Art Facility in San Jose, CA, USASAN JOSE, California - Finesse Solutions, LLC, San Jose, CA, a manufacturer of measurement and control solutions for bioprocess applications, announced its move from a facility in Santa Clara, CA, to a much larger facility in San Jose, CA. Finesse’s new address is 71 Daggett Drive, San Jose, CA, 95134. This move completes the consolidation of all Finesse departments from Irvine, CA to Silicon Valley. Cappella Inc. Secures US$17.3 Million Series C InvestmentWILMINGTON, Delaware and GALWAY, Ireland - New and existing investors complete a US$17.3 million Series C investment - Experienced medical device executive, Dr. Art Rosenthal, appointed as CEO - Aggressive launch of Sideguard(TM) Sidebranch stent in EU following recent CE Marking - Expansion of management team, R&D and manufacturing capacity in Galway, Ireland UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma PatientsPITTSBURGH, Pennsylvania, and JERUSALEM, Israel - The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the ExCell research study. Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug InteractionBOSTON - Study Shows Kowa’s Novel Synthetic Statin is Safe and Well Tolerated in Combination With Warfarin Paris Dates for CPhI Worldwide 2010MAARSSEN, Netherlands - CPhI Worldwide returns to Paris for 2010 when, with ICSE, PMEC and BioPh, the world’s leading pharma services industry event will be staged at Paris-Nord Villepinte on Tuesday 5 - Thursday 7 October. This is a week earlier than the 2009 event in Madrid, but close to the dates of the last staging in Paris, in 2006. King Fahd University For Petroleum & Minerals is First in Gulf Region to Purchase Web of Science(R) BackfilesPHILADELPHIA and LONDON - The Healthcare & Science business of Thomson Reuters today announced that King Fahd University For Petroleum & Minerals (KFUPM), has purchased Web of Science data back to 1900. KFUPM is the first university in the Saudi Arabia Consortia, and in the Gulf region, to purchase more than a century of vital data. International Researchers Call on Rheumatologists to Help Their Patients Stay Fit for WorkCOPENHAGEN - New Advice to Support the 100 Million People in the EU who Suffer From Chronic Musculoskeletal Disorders Clinical Data Presented at International Congress Showed Treatment With Neupro(R) (rotigotine) Significantly Improved Early Morning akinesia and was Generally Well Tolerated Over Four YearsBRUSSELS - For the Attention of European Accredited Medical Writers Only - Data Presented at the 13th International Congress of Parkinson’s Disease and Movement Disorders Chiesi Creates New Research Centre to Study Innovative Therapies for the Treatment of Respiratory and Special Care DiseasesPARMA, Italy - The centre, which is to be located in Parma over an area of 22,000 sq. m., will be operative from 2011 and will employ over 300 qualified researchers from both Italy and abroad. The investment is worth around euro 70 million. The aim of the centre is the study of innovative products for chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and special care diseases such as cystic fibrosis and respiratory distress syndrome in premature infants. Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R) at the European League Against Rheumatism (EULAR) Annual MeetingMAIDENHEAD, England - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage ConvaTec Launches Hydrofiber(R) Technology WebsiteICKENHAM, England - Transforming Wound Care With the Power Behind the Company’s Advanced Dressings Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry ResearchAMSTERDAM - Improving Research Discoverability and Productivity Elsevier today announced a new partnership agreement with NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data to enrich ScienceDirect content. This agreement allows for an integration of NextBio’s unique set of ontology-based semantic tools and a compilation of high quality sources of public data on ScienceDirect, providing health science, life science and chemistry researchers with a dynamic platform to improve discoverability and research productivity. NICE Acknowledge Alzheimer’s Model Faulty but do not Plan to Change RecommendationsLONDON - Mild Alzheimer’s Patients Continue to be Denied Treatment Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, have been notified by the National Institute for Health and Clinical Excellence (NICE) of their decision to continue to deny vulnerable patients the use of anti-cholinergic medicines in the treatment of mild Alzheimer’s disease. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly PatientsSEATTLE - Neurim Pharmaceuticals (www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington. The SLEEP meeting attracts the largest audience of sleep specialists in world. New Phase 3 Data Continue to Indicate that Wyeth’s Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal DiseaseCOLLEGEVILLE, Pennsylvania - New data from Phase 3 European clinical trials reinforce that Wyeth’s (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide. Jubilant to Work With Endo Pharmaceuticals on Drug DevelopmentNOIDA, India - Collaboration to Provide Endo Pharmaceuticals With New Drug Candidates in Oncology |
